Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Neurology Rheumatology Diabetes / Metabolic Mental Health / Psychiatry Women's Health Dermatology Men's Health Rare Diseases
Clinical Trial Active — Not Recruiting Phase II NCT03821610

A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC)

A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission.…

📅 05 May 2026 ⏱ 2 min read
Active — Not Recruiting
Check the registry for current status and eligibility criteria.
Status
Active — Not Recruiting
Phase
Phase II
NCT ID
NCT03821610
Start
2018-11-22
Completion
2025-10-31
ClinicaliQ Trial Snapshot
  • A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC) — Active Not Recruiting • Phase II • Oncology • NCT03821610.
  • ALL-RIC Trial Summary.
  • Trial comparing two pre-transplant chemotherapy regimens in older adults with acute lymphoblastic leukaemia to reduce disease relapse without increasing transplant mortality.

Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

The current national acute lymphoblastic leukaemia (ALL) trial in adults investigated whether a low (reduced) intensity chemotherapy regimen prior to transplant could improve the outcome of patients with ALL who are over 40 years of age. The results (60% 2 year survival) are very encouraging but patients who come to transplant with small amounts of 'residual' disease had less good outcomes. The goal of this trial is to see if a slightly stronger chemotherapy regimen (involving total body irradiation, (TBI)) can improve results by reducing the chance of the disease…

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Clinical Brief
MPs call for sunbed advertising ban to help prevent skin cancer
Oncology · BBC Health · 13 May 2026
A cross-party parliamentary report identifies that most skin cancer cases are preventable, supporting calls for stricter regulation of sunbed advertising as a…
View brief →
Guideline
Oesophago-Gastric Cancer: Assessment and Management (NICE NG83)
Oncology · 27 Mar 2026
Multimodal treatment with neoadjuvant chemotherapy followed by surgical resection improves survival for locally advanced oesophago-gastric junction and gastric adenocarcinomas. HER2 testing is…
View guideline →
Guideline
Multiple Myeloma: Diagnosis and Management (NICE NG35)
Oncology · 27 Mar 2026
Proteasome inhibitors (bortezomib, carfilzomib) combined with immunomodulatory drugs (lenalidomide) and dexamethasone have become standard first-line therapy for transplant-eligible myeloma patients. Daratumumab (anti-CD38…
View guideline →
Guideline
Colorectal Cancer: Diagnosis and Management (NICE NG151)
Oncology · 27 Mar 2026
Refer adults with rectal bleeding plus abdominal pain, change in bowel habit, weight loss, iron-deficiency anaemia, or age >60 with unexplained symptoms…
View guideline →
Guideline
Pembrolizumab for neoadjuvant and adjuvant treatment of resectable locally advanced head and neck squamous cell carcinoma
Oncology · 21 Apr 2026
Pembrolizumab is recommended as neoadjuvant treatment prior to surgery for resectable locally advanced head and neck squamous cell carcinoma, followed by adjuvant…
View guideline →
Clinical Brief
Ultrasound delays putting pregnant women and cancer patients at risk, sonographers say
Oncology · BBC Health · 28 Mar 2026
Ultrasound service capacity is insufficient due to inadequate sonographer training, creating delays that compromise care for pregnant women and cancer patients requiring…
View brief →